Saccharin

What this is

Saccharin has a long safety record but an unusually visible regulatory history. In the 1970s, high-dose rat studies linked sodium saccharin to bladder tumors; later mechanistic and epidemiologic reviews concluded the rat mechanism is not relevant to humans and no clear human bladder-cancer association has emerged. NTP removed saccharin from the Report on Carcinogens, FDA says saccharin products no longer need the earlier cancer warning, and EFSA’s 2024 re-evaluation concluded that saccharin does not damage DNA and is unlikely to be associated with human cancer risk. EFSA raised its ADI to 9 mg/kg body weight/day and found estimated EU chronic exposures below that ADI; FDA lists a U.S. ADI of 15 mg/kg body weight/day, while JECFA retains an older group ADI of 0–5 mg/kg. Regulators still manage saccharin through additive permissions and use limits rather than treating it as unrestricted. A newer California school-food law could affect products with nonnutritive sweeteners, but saccharin itself has not been singled out.

Safety Review

The critical endpoints experts review in safety assessments. This is not a prediction of harm.

High-dose rat bladder tumors drove earlier concern, but EFSA, NTP, FDA, and human epidemiology reviews consider the mechanism not relevant to humans and do not show a clear human bladder-cancer association. Current safety review focuses on use limits, EFSA's limited long-term human evidence for glucose regulation and weight outcomes, and tightened specification recommendations.